Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics (Narrative) (Details)

v3.19.1
Acquisition of Pelican Therapeutics (Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended
May 31, 2016
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Oct. 31, 2018
Business Acquisition [Line Items]          
Accrued liabilities   $ 948,906   $ 1,678,051  
Goodwill   2,189,338   $ 2,189,338  
Net loss (income)   $ (5,715,476) $ (3,321,766)    
Pelican Therapeutics, Inc. [Member]          
Business Acquisition [Line Items]          
Percentage of voting interests acquired in acquisition   85.00%   85.00% 85.00%
Cash consideration   $ 500,000      
Accrued liabilities   200,000      
Fair value of contingent consideration   100,000 0    
Goodwill   2,189,338      
In-process R&D   $ 5,900,000      
Percentage of non-controlling interest acquired   20.00%      
Amount awarded from CPRIT grant $ 15,200,000        
Total grant funds provided by CPRIT   $ 8,300,000      
Remaining grant funds to be provided by CPRIT   6,900,000      
Total matching funds provided by Company   6,000,000      
Remaing matching funds to be provided by Company   3,500,000      
Contract value   $ 7,600,000      
Pelican Therapeutics, Inc. [Member] | Stockholders [Member]          
Business Acquisition [Line Items]          
Cash consideration     $ 300,000    
Heat Biologics I, Inc. [Member]          
Business Acquisition [Line Items]          
Percentage of voting interests acquired in acquisition         80.00%